HETEROCYCLIC COMPOUNDS, THEIR USING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF STATES MEDIATED BY CXCR4 AND CCR5

FIELD: organic chemistry of heterocyclic compounds, medicine, pharmacy. ^ SUBSTANCE: invention relates to new compounds of the formula (1): and its salts wherein X means unsubstituted monocyclic (5-6-membered) ring system comprising nitrogen atom (N); or X means condensed bicyclic (9-12-membered) ri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BOGUTSKIJ DEHVID, KEHLLER EHL, BRIDZHER GARI, KROFORD DZHEJSON, SKERLDZH RENATO, SMIT KRISTOFER DENNIS, ATSMA BEM, KHARVIG KERTIS, NAN SIKVAJAO, ZOU JUANKSI, UILSON TREVOR R, MAKICHERN EHRNEST DZH, SKHOLS DOMINIK, DI FLURI ROZARIA MARIJA
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: organic chemistry of heterocyclic compounds, medicine, pharmacy. ^ SUBSTANCE: invention relates to new compounds of the formula (1): and its salts wherein X means unsubstituted monocyclic (5-6-membered) ring system comprising nitrogen atom (N); or X means condensed bicyclic (9-12-membered) ring system comprising N-atom that can be substituted with substitute -SO2-phenyl; Z represents hydrogen atom (H) or means a condensed bicyclic (9-12-membered) unsubstituted or substituted ring system comprising at least one heteroatom, N-atom; Ar represents unsubstituted phenyl ring; each among L1, L2 and L3 represents independently a bond, -CO, -SO2 or -CH2 wherein at least one among L2 and L3 must involve -CO or -SO2; L2 and L3 can represent can represent independently -CONH or -CONHCH2 also; n = 0, 1 or 2; each R1 and R2 represents independently hydrogen atom (H) or a direct (C1-C6)-alkyl chain; Y comprises at least one substituted or unsubstituted phenyl ring or 5-6-membered heteroaromatic ring comprising at least one N-atom as a heteroatom; wherein optional substituted are chosen among the group consisting of halogen atom, alkyl, -COOH, -OH or -NH2; or Y represents 6,7-dihydropyrrolo[3,4-b]pyridine-5-one; wherein ring nitrogen atom can be oxidized optionally. Also, invention relates to a pharmaceutical composition used in treatment states regulated by chemokine CXCR4 or CCR5 receptors based on these compounds. Invention provides preparing new compounds and medicinal agents based on thereof for aims in treatment of HIV- and FIV-infected patients. ^ EFFECT: valuable medicinal properties of compounds and composition. ^ 15 cl, 57 ex